Human Investing LLC Has $290,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Human Investing LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,463 shares of the biopharmaceutical company’s stock after acquiring an additional 195 shares during the period. Human Investing LLC’s holdings in Gilead Sciences were worth $290,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Valued Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the last quarter. Creative Financial Designs Inc. ADV raised its position in Gilead Sciences by 7.4% during the third quarter. Creative Financial Designs Inc. ADV now owns 2,740 shares of the biopharmaceutical company’s stock worth $230,000 after acquiring an additional 189 shares in the last quarter. Stephens Inc. AR lifted its stake in Gilead Sciences by 4.3% in the third quarter. Stephens Inc. AR now owns 38,282 shares of the biopharmaceutical company’s stock valued at $3,210,000 after acquiring an additional 1,574 shares during the last quarter. LCM Capital Management Inc grew its position in shares of Gilead Sciences by 2.2% in the 3rd quarter. LCM Capital Management Inc now owns 9,396 shares of the biopharmaceutical company’s stock valued at $788,000 after acquiring an additional 206 shares during the period. Finally, Reston Wealth Management LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth about $63,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 36,847 shares of company stock worth $3,033,340 over the last 90 days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded up $0.08 on Friday, reaching $88.90. 1,024,500 shares of the stock were exchanged, compared to its average volume of 6,997,148. The firm’s 50 day moving average is $83.54 and its 200-day moving average is $73.97. The firm has a market cap of $110.68 billion, a PE ratio of 108.32, a P/E/G ratio of 3.07 and a beta of 0.18. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $89.74.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm had revenue of $6.95 billion for the quarter, compared to the consensus estimate of $6.64 billion. As a group, analysts anticipate that Gilead Sciences, Inc. will post 3.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on GILD shares. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Barclays increased their price target on Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective for the company. Finally, Piper Sandler reissued an “overweight” rating and issued a $95.00 price objective on shares of Gilead Sciences in a research report on Wednesday, September 11th. Ten analysts have rated the stock with a hold rating, eleven have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $86.85.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.